Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-Invasive Bladder Carcinoma × Immunotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14 Carcinoma, Hepatocellular 6 Melanoma 5 Squamous Cell Carcinoma of Head and Neck 4 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Rectal Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Triple Negative Breast Neoplasms 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm, Residual 2 Neoplasm Metastasis 2 Hyperthermia 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Breast Neoplasms 2 Uveal Melanoma 1 Turcot syndrome 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Recurrence 1 Radiation Pneumonitis 1 Prostatic Neoplasms 1 Pancreatic Cancer Liver Metastases 1 Neoplasms, Glandular and Epithelial 1

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡